在LMICs中药物开发:新兴的印度模式能否引领东南亚地区?
Bharat Pant1,2, Jayant Goda3,2, Vikram Gota1,2
1Department of Clinical Pharmacology, Advanced Centre for Treatment Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, Maharashtra, 410210, India.
The Lancet regional health. Southeast Asia
|September 9, 2024
概括
东南亚国家正在开发新型药物,反映印度.
科学领域:
- 制药发展 制药发展
- 药物发现 药物发现
- 全球卫生公平性全球卫生公平性
背景情况:
- 东南亚的低收入和中等收入国家 (LMICs) 正在推动药物开发.
- 这反映了印度走向制药独立的旅程.
- 该地区正在摆脱对发达国家机构的依赖.
研究的目的:
- 分享在LMICs药物开发挑战的经验和潜在解决方案.
- 提供印度药物开发之旅的见解.
- 帮助其他LMIC在药物创新的导航.
主要方法:
- 这个观点讨论了基于国家经验的挑战和解决方案.
- 它强调了药物开发中的公私伙伴关系.
- 隐含地引用了印度,印度尼西亚和越南的案例.
主要成果:
- 塔塔纪念中心拥有大量药物,其中两种药物最近获得批准.
- 印度尼西亚和越南正在探索用于药物开发的公私合作伙伴关系.
- 尽管取得了进展,但在资金和监管批准方面仍然存在挑战.
结论:
- 在药物开发方面,LMICs面临重大障碍,包括资金和监管流程.
- 合作努力和分享国家经验对于进步至关重要.
- 在国家范围内开发新药是可以实现的,对LMICs来说是有益的.
相关概念视频
Drug Discovery: Overview
7.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.6K
Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Analysis of Population Pharmacokinetic Data
240
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
240
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Model Approaches for Pharmacokinetic Data: Physiological Models
36
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
36
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
64
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
64


